Related Experiment Video
Updated: May 18, 2026

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
Published on: November 8, 2018
Lysine restricted diet for pyridoxine-dependent epilepsy: first evidence and future trials
Clara D M van Karnebeek1, Hans Hartmann, Sravan Jaggumantri
1Division of Biochemical Diseases, Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, Canada.
Insights
Dietary lysine restriction is safe and effective for children with pyridoxine-dependent epilepsy (PDE) caused by antiquitin deficiency. It reduces neurotoxic biomarkers and improves developmental outcomes and seizure control.
Area of Science:
- Neuroscience
- Metabolic Disorders
- Pediatric Neurology
Background:
- Pyridoxine-dependent epilepsy (PDE) is a rare genetic disorder caused by antiquitin (ATQ) deficiency.
- Accumulation of neurotoxic metabolites like pipecolic acid and α-aminoadipic semialdehyde (AASA) contributes to neurological damage in PDE.
- Current treatment involves pyridoxine therapy, but adjunctive strategies are needed.
Purpose of the Study:
- To evaluate the efficacy and safety of dietary lysine restriction as an adjunct to pyridoxine therapy in children with ATQ deficiency-related PDE.
- To assess the impact of lysine restriction on biochemical markers, seizure control, and developmental/cognitive outcomes.
Main Methods:
- An observational study involving seven children with confirmed ATQ deficiency.
- Implementation of dietary lysine restriction with regular nutritional monitoring.
- Evaluation of biochemical markers (pipecolic acid, AASA, P6C) in body fluids.
- Assessment of developmental/cognitive outcomes using standardized tests and parental reports.
Main Results:
- Lysine restriction was well-tolerated with good compliance and no reported adverse events.
- Significant reductions observed in plasma pipecolic acid (20-67%), urinary AASA (13-72%), plasma AASA (45%), and plasma P6C (42%).
- Improvement in age-appropriate skills in 4/5 patients with pre-existing delays; seizure control maintained or improved in 6/7 children.
- A single patient with diet interruption showed clinical deterioration and decreased CSF pipecolic acid (87.2%) and AASA (81.7%).
Conclusions:
- Dietary lysine restriction is a safe and well-tolerated adjunctive therapy for PDE caused by ATQ deficiency.
- It effectively reduces neurotoxic biomarkers and shows potential for improving developmental outcomes and seizure control.
- Further high-level evidence is needed, supported by the establishment of an international PDE consortium and research infrastructure.
Objective:
To evaluate the efficacy and safety of dietary lysine restriction as an adjunct to pyridoxine therapy on biochemical parameters, seizure control, and developmental/cognitive outcomes in children with pyridoxine-dependent epilepsy (PDE) caused by antiquitin (ATQ) deficiency.
Methods:
In this observational study, seven children with confirmed ATQ deficiency were started on dietary lysine restriction with regular nutritional monitoring. Biochemical outcomes were evaluated using pipecolic acid and α-aminoadipic semialdehyde (AASA) levels in body fluids; developmental/cognitive outcomes were evaluated using age-appropriate tests and parental observations.
Results:
Lysine restriction was well tolerated with good compliance; no adverse events were reported. Reduction in biomarker levels (measurement of the last value before and first value after initiation of dietary lysine restriction) ranged from 20 to 67% for plasma pipecolic acid, 13 to 72% for urinary AASA, 45% for plasma AASA and 42% for plasma P6C. For the 1 patient in whom data were available and who showed clinical deterioration upon interruption of diet, cerebrospinal fluid levels decreased by 87.2% for pipecolic acid and 81.7% for AASA. Improvement in age-appropriate skills was observed in 4 out of 5 patients showing pre-diet delays, and seizure control was maintained or improved in 6 out 7 children.
Conclusions:
This observational study provides Level 4 evidence that lysine restriction is well tolerated with significant decrease of potentially neurotoxic biomarkers in different body compartments, and with the potential to improve developmental outcomes in children with PDE caused by ATQ deficiency. To generate a strong level of evidence before this potentially burdensome dietary therapy becomes the mainstay treatment, we have established: an international PDE consortium to conduct future studies with an all-inclusive integrated study design; a website containing up-to-date information on PDE; a methodological toolbox; and an online registry to facilitate the participation of interested physicians, scientists, and families in PDE research.
Related Concept Videos
Antiepileptic Drugs: Glutamate Antagonists
Lysosomal Hydrolases
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...

